Table 2.
Characteristics of hepatic gene expression study patients.
| Study data | HC (n = 10) | AH (n = 12) | SAH (n = 18) | exAH (n = 11) | NAFLD (n = 9) | HCV (n = 10) | HCV-C (n = 9) |
|---|---|---|---|---|---|---|---|
| Sex (female) | 3 | 5 | 7 | 4 | 7 | 5 | 3 |
| Age (years) | 32 (29–51) | 52 (48–59) | 51 (47–58) | 49 (48–56) | 50 (43–53) | 48 (43–63) | 61 (51–66) |
| Total bilirubin (μmol/L) | 10.26 (8.55–11.97) | 20.52 (11.97–25.66) | 324.97 (210.37–456.67) | 278.79 (189.85–415.62) | 10.26 (6.84–15.39) | 12.83 (10.26–17.10) | 18.81 (13.34–28.22) |
| Creatinine (μmol/L) | 70.74 (65.43–79.58) | 53.05 (52.17–68.08) | 69.85 (53.94–88.42) | 61.01 (46.86–64.55) | 92.84 (74.27–97.26) | 88.42 (86.65–97.26) | 88.42 (73.39–97.26) |
| Albumin (g/L) | 46 (43–46) | 45 (42–47) | 29 (23–33) | 24 (20–30) | 45 (44–46) | 44 (42–47) | 41 (43–45) |
| INR | 1.03 (0.99–1.06) | 1.00 (0.90–1.00) | 1.60 (1.20–3.30) | 1.80 (1.60–2.60) | 1.19 (1.06–1.35) | 1.21 (1.01–1.40) | 1.24 (1.16–1.38) |
| Ascites (g/L) | 0 | 0 | 14 | 7 | 0 | 0 | 0 |
| Child-Pugh score | N/A | N/A | 11.0 (9.0–11.7) | 10.7 (9.0–12.0) | N/A | N/A | 5.0 (5.0–5.0) |
| MELD | N/A | N/A | 24.0 (22.0–27.7) | 24.5 (21.4–27.2) | N/A | N/A | 10.0 (8.5–12.0) |
Data are presented as n or median (25th and 75th percentiles).
Abbreviations: AH, alcoholic hepatitis group; exAH, explants from patients with SAH who underwent transplantation; HC, healthy control; HCV, non cirrhotic HCV infection group; HCV-C, compensated HCV-related cirrhosis group; INR, international normalized ratio; MELD, model for end-stage liver disease; NAFLD, non-alcoholic fatty liver disease group; SAH, severe alcoholic hepatitis group.